---
title: "Ping An Biomedical Co., Ltd. (PASW.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PASW.US.md"
symbol: "PASW.US"
name: "Ping An Biomedical Co., Ltd."
industry: "Distributors"
datetime: "2026-05-21T15:00:37.642Z"
locales:
  - [en](https://longbridge.com/en/quote/PASW.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PASW.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PASW.US.md)
---

# Ping An Biomedical Co., Ltd. (PASW.US)

## Company Overview

Ping An Biomedical Co., Ltd., through its subsidiaries, provides supply chain management services in the apparel industry in China, Hong Kong, Cambodia, and Europe. The company offers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. It also engages in the manufacturing and trading of yarns, textiles, and finished garments; real estate property investment; and warehousing services. The company serves brand owners, textile manufacturers, apparel sourcing agents, and online fashion and garment retailers.

| Item | Detail |
|------|--------|
| Industry | Distributors |
| Exchange | US Market |
| Website | [newbrandcashmere.com](https://newbrandcashmere.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: D (0.64)**

**Industry**: Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -61.38% |  |
| Net Profit YoY | -890.03% |  |
| P/B Ratio | 2.84 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18059750.00 |  |
| Revenue | 4734421.10 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -67.43% | E |
| Profit Margin | -37.57% | E |
| Gross Margin | 2.78% | E |
| Revenue YoY | -61.38% | E |
| Net Profit YoY | -890.03% | E |
| Total Assets YoY | 18.51% | A |
| Net Assets YoY | 719.81% | A |
| Cash Flow Margin | 50.10% | C |
| OCF YoY | -61.38% | E |
| Turnover | 0.55 | C |
| Gearing Ratio | 33.87% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ping An Biomedical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-61.38%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-890.03%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.84",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "18059750.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4734421.10",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-67.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-37.57%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "2.78%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-61.38%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-890.03%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.51%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "719.81%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "50.10%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-61.38%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.87%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.15 | 23/27 | - | - | - |
| PB | 2.84 | 15/27 | 2.98 | 0.64 | 0.55 |
| PS (TTM) | 3.81 | 20/27 | 1.90 | 1.23 | 0.75 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | GigaCloud Tech (GCT.US) | B | B | A | D | B | B |
| 02 | Gold.com (GOLD.US) | C | A | A | E | A | B |
| 03 | Weyco (WEYS.US) | B | D | A | A | C | B |
| 04 | Alliance ENT (AENT.US) | B | B | A | D | C | B |
| 05 | J-Long (JL.US) | B | A | A | B | C | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PASW.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PASW.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PASW.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PASW.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**